Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin C Müller

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Cell Cycle (Georgetown, Tex.)|January 12, 2011
Impact of BCR-ABL mutations on patients with chronic myeloid leukemiaAndreas Hochhaus, Paul La Rosée, Martin C Müller, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Cause and management of therapy resistanceAndreas Hochhaus, Thomas Schenk, Philipp Erben, et al.
Blood|November 24, 2012
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemiaMatthias Horn, Ingmar Glauche, Martin C Müller, et al.
Acta Haematologica|June 5, 2004
Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemiaMartin C Müller, Tanja Hördt, Peter Paschka, et al.
Haematologica|July 8, 2008
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemiaThomas Ernst, Jana Hoffmann, Philipp Erben, et al.
Leukemia & Lymphoma|December 7, 2021
<i>SOCS-2</i> gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatmentDamla Buket Egeli, Benjamin Hanfstein, Michael Lauseker, et al.
Experimental Neurology|February 3, 2009
Exogenous reelin prevents granule cell dispersion in experimental epilepsyMartin C Müller, Matthias Osswald, Stefanie Tinnes, et al.
Biomarker Research|March 4, 2016
c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemiaWiltrud Prinzhorn, Michael Stehle, Helga Kleiner, et al.
Critical Reviews in Oncology/Hematology|December 5, 2017
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panelMartin C Müller, Francisco Cervantes, Henrik Hjorth-Hansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemiaAndreas Burchert, Martin C Müller, Philippe Kostrewa, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Cell Cycle (Georgetown, Tex.)|January 12, 2011
Impact of BCR-ABL mutations on patients with chronic myeloid leukemiaAndreas Hochhaus, Paul La Rosée, Martin C Müller, et al.
Best Practice & Research. Clinical Haematology|December 5, 2009
Cause and management of therapy resistanceAndreas Hochhaus, Thomas Schenk, Philipp Erben, et al.
Blood|November 24, 2012
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemiaMatthias Horn, Ingmar Glauche, Martin C Müller, et al.
Acta Haematologica|June 5, 2004
Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemiaMartin C Müller, Tanja Hördt, Peter Paschka, et al.
Haematologica|July 8, 2008
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemiaThomas Ernst, Jana Hoffmann, Philipp Erben, et al.
Leukemia & Lymphoma|December 7, 2021
<i>SOCS-2</i> gene expression at diagnosis does not predict for outcome of chronic myeloid leukemia patients on imatinib treatmentDamla Buket Egeli, Benjamin Hanfstein, Michael Lauseker, et al.
Experimental Neurology|February 3, 2009
Exogenous reelin prevents granule cell dispersion in experimental epilepsyMartin C Müller, Matthias Osswald, Stefanie Tinnes, et al.
Biomarker Research|March 4, 2016
c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemiaWiltrud Prinzhorn, Michael Stehle, Helga Kleiner, et al.
Critical Reviews in Oncology/Hematology|December 5, 2017
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panelMartin C Müller, Francisco Cervantes, Henrik Hjorth-Hansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemiaAndreas Burchert, Martin C Müller, Philippe Kostrewa, et al.
Pageof 8